Bluebird Bio Inc. (BLUE) Given a $100.00 Price Target at Maxim Group
A number of other analysts have also recently weighed in on BLUE. Cantor Fitzgerald initiated coverage on shares of Bluebird Bio in a research note on Thursday, June 2nd. They issued a hold rating and a $42.00 target price on the stock. Vetr cut shares of Bluebird Bio from a strong-buy rating to a sell rating and set a $44.44 target price on the stock. in a research note on Wednesday, June 8th. Leerink Swann reissued a buy rating on shares of Bluebird Bio in a research note on Monday, June 13th. BTIG Research reissued a buy rating and issued a $72.00 target price on shares of Bluebird Bio in a research note on Wednesday, June 29th. Finally, Jefferies Group reissued a buy rating and issued a $80.00 target price on shares of Bluebird Bio in a research note on Friday, July 8th. Five research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Bluebird Bio presently has an average rating of Buy and a consensus target price of $90.25.
Shares of Bluebird Bio (NASDAQ:BLUE) traded up 3.1586% during trading on Thursday, hitting $68.5076. 416,079 shares of the stock traded hands. The firm has a 50 day moving average price of $59.55 and a 200-day moving average price of $49.06. Bluebird Bio has a one year low of $35.37 and a one year high of $106.95. The company’s market cap is $2.55 billion.
Bluebird Bio (NASDAQ:BLUE) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported ($1.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.44) by $0.15. Bluebird Bio had a negative return on equity of 24.85% and a negative net margin of 3,512.13%. The company had revenue of $1.55 million for the quarter, compared to the consensus estimate of $2.01 million. During the same quarter in the previous year, the firm posted ($1.57) EPS. The business’s revenue for the quarter was down 68.6% compared to the same quarter last year. Analysts anticipate that Bluebird Bio will post ($6.18) earnings per share for the current fiscal year.
In related news, insider Eric Sullivan sold 2,807 shares of the stock in a transaction on Wednesday, July 20th. The shares were sold at an average price of $45.04, for a total transaction of $126,427.28. Following the completion of the transaction, the insider now owns 4,656 shares in the company, valued at $209,706.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Davidson sold 1,000 shares of the stock in a transaction on Friday, July 15th. The shares were sold at an average price of $45.08, for a total transaction of $45,080.00. Following the completion of the sale, the insider now owns 10,600 shares of the company’s stock, valued at approximately $477,848. The disclosure for this sale can be found here. Corporate insiders own 3.50% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Pacad Investment Ltd. purchased a new stake in shares of Bluebird Bio during the first quarter worth approximately $829,000. TIAA CREF Investment Management LLC boosted its stake in shares of Bluebird Bio by 134.0% in the first quarter. TIAA CREF Investment Management LLC now owns 339,424 shares of the company’s stock worth $14,426,000 after buying an additional 194,367 shares in the last quarter. Teachers Advisors Inc. boosted its stake in shares of Bluebird Bio by 5.5% in the first quarter. Teachers Advisors Inc. now owns 46,048 shares of the company’s stock worth $1,957,000 after buying an additional 2,416 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Bluebird Bio by 26.1% in the first quarter. Franklin Resources Inc. now owns 965,561 shares of the company’s stock worth $41,036,000 after buying an additional 199,900 shares in the last quarter. Finally, BlackRock Inc. boosted its stake in shares of Bluebird Bio by 341.0% in the first quarter. BlackRock Inc. now owns 4,569 shares of the company’s stock worth $194,000 after buying an additional 3,533 shares in the last quarter.
About Bluebird Bio
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Receive News & Stock Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related stocks with our FREE daily email newsletter.